

2018 Procrit[®] (epoetin alfa) Prior Authorization Request

(You must complete both pages.)

Fax completed form to: 1-800-639-9158 For urgent requests, please call: 1-800-551-2694 Patient information Prescriber information Physician specialty Patient name Today's date NPI/DEA number Patient insurance ID number Physician name Patient address, city, state, ZIP Physician address, city, state, ZIP M.D. office telephone number Patient home telephone number Patient date of birth M.D. office fax number Gender ☐ Male ☐ Female Diagnosis and medical information Medication requested Diagnosis ☐ Anemia due to chronic kidney disease (CKD) □ Procrit ☐ Anemia due to end stage renal disease (ESRD) with DIALYSIS Anemia due to myelosuppressive anticancer chemotherapy Anemia due to zidovudine therapy in an HIV-infected patient ☐ Surgical procedure -Transfusion of blood product, allogeneic; prophylaxis Anemia due to myelodysplastic syndromes (MDS) Anemia in congestive heart failure (CHF) ☐ Anemia in rheumatoid arthritis (RA) Anemia due to hepatitis C treatment (ribavirin in combination with either interferon alfa or peginterferon alfa) ☐ Anemia in primary myelofibrosis ☐ Post-polycythemia vera myelofibrosis ☐ Post-essential thrombocythemia myelofibrosis Other diagnosis/(ICD10): Strength and route of administration Expected length of therapy Quantity Day supply Please check all boxes that apply: ☐ Restart ☐ New start Renewal 1. Where is medication being administered? ☐ Patient's home (self-administered) Office administered (office supplies drug) / J CODE: ☐ Office administered (pharmacy supplies drug) ☐ Dialysis center 2. All covered Part D drugs on any tier of the plan's formulary would not be as effective for the enrollee as the requested formulary drug and/or would likely have adverse effects for the enrollee. 3.

☐ Yes □ No Is the patient on dialysis? ? If yes, please answer the following: ☐ Yes ☐ No Does the prescriber (i.e. nephrologist, nurse practitioner, or physician assistant) receive a monthly capitation payment to manage ESRD patients' care? ☐ Yes ☐ No Is the Procrit to be used for an ESRD-related condition? 4. For all uses EXCEPT surgical procedures, please answer the following: ☐ Yes ☐ No Was the patient's hemoglobin (Hgb) level prior to treatment with erythropoietin less than 10 g/dL for all diagnoses or less than 9 g/dL for anemia in CHF only (Please note: pre-treatment value is the Hgb level when the patient had received no erythropoietin in the previous month)

continued on next page

Fax Confidentiality Notice: The information contained in this transmission is confidential, proprietary or privileged and may be subject to protection under the law, including the Health Insurance Portability and Accountability Act (HIPAA). The message is intended for the sole use of the individual or entity to whom it is addressed. If you are not the intended recipient, you are notified that any use, distribution or copying of the attached material is strictly prohibited and may subject you to criminal or civil penalties. If you received this transmission in error, please notify us immediately by telephone at 1-800-551-2694.



Page 2 of 2

Please check all boxes that apply (continued):	
5. Yes No Is Procrit requested for the treatment of anemia due to primary myelofibrosis (MF), post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis? If YES, please answer the questions below: Yes No Does the patient have symptomatic anemia?	
Yes No For initial therapy, was the pretreatment serum erythropoietin	level less than 500 mU/mL.
6. Yes No Is Procrit requested for a patient undergoing an elective, noncardiac, nonvascular surgery? If YES, please answer the following question:	
☐ Yes ☐ No Is the pretreatment (perioperative) Hgb greater than 10 g/dL bu	ut not more than 13 g/dL?
7. For new starts and renewals:	
Disease complete this position halour only if your nations does not most the standard requirements listed shave	
Please complete this section below only if your patient does not meet the standard requirements listed above. Please explain why your patient should be considered for exception although not meeting the plan's suggested PA criteria. Statement	
should include specifically which requirement is not met and why patient should be exempt from meeting this requirement. (Please note any information that is incomplete or illegible will delay the review process.)	
8. Yes No Procrit is not covered for patients receiving chemotherapy with curative intent or patients with myeloid cancer. Is the patient receiving chemotherapy with curative intent or does the patient have a diagnosis of myeloid cancer?	
9 Other supporting information:	
*NOTE: Requests that are subject to prior authorization (or any other utilization management requirement), may require supporting information. Please attach supporting information, as necessary, for your request.	
I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that documentation supporting this information is available for review if requested by the health plan sponsor, or, if applicable, a state or	
federal regulatory agency. I understand that any person who knowingly makes or causes to be made a false record or statement that is material to a claim ultimately paid by the United States government or any state government may be subject to civil penalties and treble	
damages under both the federal and state False Claims Acts. See, e.g., 31 U.S.C. §§ 3729-3733. By signing this form, I represent that I have obtained patient consent as required under applicable state and federal law, including but not limited to the Health Information Portability and Accountability Act (HIPAA) and state re-disclosure laws related to HIV/AIDS.	
Prescriber signature	Date

Fax Confidentiality Notice: The information contained in this transmission is confidential, proprietary or privileged and may be subject to protection under the law, including the Health Insurance Portability and Accountability Act (HIPAA). The message is intended for the sole use of the individual or entity to whom it is addressed. If you are not the intended recipient, you are notified that any use, distribution or copying of the attached material is strictly prohibited and may subject you to criminal or civil penalties. If you received this transmission in error, please notify us immediately by telephone at 1-800-551-2694.